BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3470165)

  • 1. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
    Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
    Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.
    Sulh H; Koren G; Whalen C; Soldin S; Zipursky A; Greenberg M
    Clin Pharmacol Ther; 1986 Dec; 40(6):604-9. PubMed ID: 3465489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.
    Zimm S; Collins JM; O'Neill D; Chabner BA; Poplack DG
    Clin Pharmacol Ther; 1983 Dec; 34(6):810-7. PubMed ID: 6580097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
    Innocenti F; Danesi R; Di Paolo A; Loru B; Favre C; Nardi M; Bocci G; Nardini D; Macchia P; Del Tacca M
    Cancer Chemother Pharmacol; 1996; 37(5):409-14. PubMed ID: 8599862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
    Ogungbenro K; Aarons L;
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacology of orally administered chemotherapy. A reappraisal.
    Poplack DG; Balis FM; Zimm S
    Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
    Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
    Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
    Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
    Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
    Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
    Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
    J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
    Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
    Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
    Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
    Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of food on the oral administration of 6-mercaptopurine.
    Burton NK; Barnett MJ; Aherne GW; Evans J; Douglas I; Lister TA
    Cancer Chemother Pharmacol; 1986; 18(1):90-1. PubMed ID: 3757164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
    Lafolie P; Hayder S; Björk O; Peterson C
    Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
    Hayder S; Björk O; Lafolie P
    Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.
    Lönnerholm G; Kreuger A; Lindström B; Myrdal U
    Pediatr Hematol Oncol; 1989; 6(2):105-12. PubMed ID: 2702064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
    Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
    Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro.
    Liliemark J; Pettersson B; Peterson C
    Leuk Res; 1992; 16(3):275-80. PubMed ID: 1373210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
    Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
    Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.